Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Participants

Running, not enrolling · Phase 1

Conditions studied: Pain

In brief

The purpose of the study is to evaluate the pharmacokinetics (PK) of Suzetrigine (SUZ) and its metabolite in the absence and presence of efavirenz, a moderate CYP3A inducer. In addition, the purpose is to evaluate the safety and tolerability of SUZ when administered in the absence and presence of efavirenz.

Key facts

Study ID

NCT07570069

Run by

Vertex Pharmaceuticals Incorporated

People needed

18

Starts

2026-05-07

Expected to finish

2026-07-11

Last updated by the study team

2026-06-30

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

Where it is running

• ICON - Utah - Salt Lake City Office — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.